Allosteric ligands of GABA A receptors exist in many different chemotypes owing to their great usefulness as therapeutics, with benzodiazepines being among the best known examples. Many allosteric binding sites have been described, among them a site at the extracellular interface between the alpha principal face and the beta complementary face (aþ/b-). Pyrazoloquinolinones have been shown to bind at aþ/bbinding sites of GABA A receptors, exerting chiefly positive allosteric modulation at this location. In order to further explore molecular determinants of this type of allosteric modulation, we synthesized a library of ligands based on the PQ pharmacophore employing a ring-chain bioisosteric approach. In this study we analyzed the structure-activity-relationship (SAR) of these novel ligands based on an azo-biaryl structural motif in a1b3 GABA A receptors, indicating interesting novel properties of the compound class.
Introduction
GABA A receptors are pentameric ligand-gated ion channels and belong to the cys-loop receptor superfamily. They are arranged in homo-or heteropentameres, which are assembled from a pool of 19 different subunits producing a large variety of receptor subtypes with distinct pharmacology. The most common receptor is formed by 2a, 2b and 1g subunits. In the binary receptors, the g subunit that forms the interface where the BDZ binding site is placed (aþ/g-), is thought to be replaced by an additional b subunit [1] . The five subunits forming the pentamer are arranged in counter clockwise fashion e.g. ababb, forming five±interfaces (aþ/b-; bþ/a-; aþb-; bþ/b-; bþ/a with GABA sites being formed by the bþ/a-interfaces) in the case of binary ab receptors (Fig. 1, panel A) .
GABA A receptors contain a relatively large number of allosteric binding sites and, consequently, also a large and chemically diverse set of allosteric ligands of GABA A receptors exist. Among the allosteric modulators, pyrazoloquinolinones (PQs) ( Fig. 1, panel B ) have been largely investigated for their pharmacological properties starting from the 1980s [2] . They were predominantly described as high affinity ligands binding at the benzodiazepine binding site (historically termed benzodiazepine-receptors) [3] . More recent functional studies revealed that PQs modulate GABA A receptors by interacting with an alternative site at the extracellular interface between the alpha principal face and the beta complementary face (aþ/b-). Given the existence of six alpha and three beta isoforms, in theory eighteen such sites may be present and potentially suitable to target distinctive receptor isoforms [4e6] . Thus, many modifications of the general PQ scaffold were generated for identifying subtype-selective compounds [6, 7] .
Here we aimed to generate a novel scaffold that is strongly inspired by the pharmacophoric descriptors of pyrazoloquinolinones that may lend itself to substantial improvements both in terms of pharmacokinetic and ADMET properties as well as the potential for subtype selectivity. Even though many chemotypes have been described already targeting this family of receptors, many challenges remained unmet [8] . This is in part due to the high homology among subunits, which makes it difficult to develop and to characterize genuinely selective substances as many of the interaction sites for allosteric modulators contain highly conserved ligand recognition motifs [9] . Interestingly, so far only few of the existing interaction sites for allosteric modulators have been targeted extensively by compound development efforts. Traditionally, ligands for the benzodiazepine recognition sites have been developed towards subtype selectivity [8, 10] .
Considerable efforts were directed also towards ligands that target so-called anesthetic sites, which are a heterogenous group of binding sites that are localized in the transmembrane domain [9, 11] . The allosteric sites that are present in the extracellular domain, such as the high affinity benzodiazepine site at the extracellular aþ/gÀ interfaces and the modulatory PQ site at the aþ/bÀ interfaces display much higher variability in sequence and local structure, compared to the highly conserved transmembrane domain, and are thus considered superior candidates for the development of selective compounds [5] .
In this work we describe the design, synthesis and biological properties of a series of new compounds with a highly similar pharmacophore as displayed by the PQs in a1b3 GABA A receptors, for which the most extensive exploration of differently substituted pyrazoloquinolinone's modulatory properties is available [12] . While this receptor subtype is of relatively low abundance in the mammalian brain [4, 13] , it has numerous advantages for the expression in heterologous cell systems and for the pharmacological testing of compounds that only require alpha and beta subunits for their activity [12, 14] . For the purposes of this study, this receptor composition offers the advantage of lacking the benzodiazepine binding site and thus reducing the number of potentially interfering additional allosteric effects.
Results and discussion

Pharmacophore features and ligand-design
The most common modifications of the pyrazoloquinolinones scaffold concern ring A and ring D, which were modified both in terms of position of substituents and dimension of the ring. For example, as reported by Varagic et al. [12] , changes in the position of the substituents on ring A had significant impact on the potency of the PQ derivatives, whereas in combination with changes in the position and functional group of the substituent on ring D influenced the modulatory efficacy of different receptor subtypes [12] . In the same work, the replacement of ring A with an aliphatic ring resulted in a null modulator at the benzodiazepine (BZ) binding site, and the replacement with a thiophene led to the synthesis of a non-binder. Modifications on rings B and C are less investigated: the replacement of the pyrazolo ring C with a triazolo system gave compounds with high affinity for the aþ/b-binding site [15] . In order to gain more insight on the effect of changes of ring B and C, we designed a new scaffold with several modifications (Fig. 1, panel  B) .
More specifically the pyridine ring is replaced by a pyrrole moiety, leading to a reduction in the size of ring B; and the pyrazolone which formed ring C is opened following the concept of ring-chain bioisosterism. Moreover, a carboxylic acid group is attached to ring B and the D ring is connected to the core of the molecule via an azo group. The insertion of a carboxylic acid function was considered in order to increase the poor solubility, which would help to overcome one of the major issues of the pyrazoloquinolinones [16] . Before starting the actual synthesis, the pharmacophores of PQs and of the new scaffold were generated and compared with the program LigandScout 4.2.1 available from Inte:Ligand GmbH [17, 18] , in order to assess whether the new compound class could potentially occupy the same binding site. As shown in Fig. 2a , the pharmacophore of PQ consists of eight features: two hydrophobic features -ring A and D -, two hydrogen bond acceptors -the nitrogen and the ketone of the pyrazolo ring -, depicted as yellow and red spheres respectively; three aromatic rings -labelled A, B and D -, and one hydrogen bond donor e quinoline nitrogen-represented with blue rings and a green arrow respectively. In the indole-derivative pharmacophore, all these features are conserved: the two hydrophobic interactions of the A and D rings (yellow spheres); the aromatic feature of the quinoline is replaced by the one of the indole (blue ring) and the hydrogen bond donor is preserved (green arrow). In addition to the two hydrogen bond acceptors of the PQ scaffold, two more hydrogen bond acceptors and a negative ionizable area were observed in the new pharmacophore (b). The superposition of the two pharmacophores showed a good overlapping of the common features ( Fig. 2 c, d), therefore, based on this similarity we expected activity of the newly designed compounds on GABA A receptors.
Chemistry
A series of nine compounds ( Fig. 3 ) was synthesized and tested for their activity on a1b3 receptors. In order to explore the activity on these receptors, chemically different substituents were chosen, both for position 5 (-H, -Cl, -OMe) and 4(-Me, -OMe, -Br).
3-(Aryldiazenyl)-1H-2-carboxylic acids 6a-g were obtained using a four-step synthetic route as outlined in Scheme 1: Ethyl-(2arylhydrazinylidene)-propanoates 2a-b were synthesized according to a modified literature procedure starting from the corresponding hydrazine [19] . Treatment of 2b with polyphosphoric acid at 110 C gave indolecarboxylates 3b in moderate yields [19] . Indole carboxylate 3c was obtained exploiting a published procedure directly from p-methoxyphenylhydrazine [20] . The diazonium salt solutions 4a-c were prepared by the treatment of a solution of methyl-, methoxy-, or bromo-aniline, respectively, in HCl, with a solution of NaNO 2 in ice-cold water. The diazonium salt solutions were immediately used for the azo coupling with carboxylates 3a-c in the presence of excess potassium carbonate in DMF. The ester precursors were obtained in good yields (65e82%), except for the formation of 5e (30% yield). Ultimately, hydrolysis of the ester function with a 2 M solution of NaOH gave the final products in 50e70% yield. The structure of the final compound 6b was supported by X-ray crystallography ( Fig. 4 ). Furthermore, it has to be mentioned that all final compounds 6 showed improved solubility in MeOH and DMSO as compared to their PQ counterparts.
Pharmacological analysis
Two electrode voltage clamp measurements were performed to assess modulatory activity in a1b3 GABA A receptors similar as described previously [12] . Fig. 5 provides an overview of the compounds exhibited modulatory activity in a1b3, with efficacy ranging from moderate to strong. The inactive compounds 5a and 5b bear an ester group in position 2 (ring B). Hydrolysis of the ester group on ring B to a carboxylic acid group as in 6a and 6b enabled modulation of 200% and 2000% respectively, at 30 mM compound concentration (which is the solubility limit for the analogous PQs) ( Fig. 5A ). This finding suggests that the carboxylic acid group on ring B is essential for inducing modulation, as indicated by the overlapping of the hydrogen bond acceptor feature of the carboxylic acid of the indole derivatives and the same feature of the carbonyl moiety of the PQs.
Keeping this in mind, different modifications on ring A (position 5) and ring D (position 4 0 ) were introduced in order to test the impact of the substituents on the modulatory efficacy. By analyzing the obtained results some general trends could be identified, which are numerically displayed in panel b of Fig. 5 and graphically summarized in Fig. 6 . When looking solely on the different substituents R 1 , the impact on efficacy follows the rank order chloro (1800e3000%, 6f, 6b and 6d) > methoxy (300%e830%, compounds 6e, 6c and 6g) > H (200%, 6a). When analyzing the influence of the R 2 residue within a series (R 1 -Cl or R 1 -OMe series) it was found that a bromo-substituent in the R 2 position results in the highest efficacy in both series (830% 6e and 3000% 6d, respectively). The difference between a methoxy or methyl group in R 2 is not very pronounced for both series. In the 5-methoxy series, the efficacy with R 2 ¼ methoxy (6c, 300%) is a bit lower as compared to R 2 ¼ methyl (6g, 400%). In the 5-chloro series compound 6f bearing a R 2 -methyl group, exerted 1800% of the GABA elicited current, whereas up to 2000% were measured with a methoxy group on the same position (6b). As expected from the pharmacophore analysis, the new indole-derivatives displayed modulatory properties. To further investigate the similarity of these compounds to the accordingly substituted PQs, we compared their activity with the one of the corresponding published PQs (Fig. 7 ). As shown in Fig. 7 , the modulation of the indole derivatives is comparable or slightly higher in case of the 5-chloroindole derivatives (panel A 6b vs 7a, and B 6f vs. 7b), and generally significantly lower in the case of the 5-methoxyindole derivatives, compared to the corresponding PQs (panel C 6c vs. 7c, and D 6g vs. 7d). Assuming that both classes of compound share the aþ/bÀ binding site, this data seem to suggest that the modifications of the PQ scaffold towards the indole derivatives 6, resulted in a different interaction between the receptor and the R5-substituent on ring A. The corresponding data show that R 1 Cl-substituted indole compounds 6b/6f display much higher modulation than the R 1 -MeO substituted derivatives 6c/6g. This drop of modulation when increasing the size of the substituent on ring A could be attributed to the more flexible geometry of the indole-derivatives which might result in having the methoxy group in an area of the binding site with insufficient space or a repulsive interaction. On the other hand, we do not see a similarly strong effect when comparing the data of compounds 6b vs. 6f and 6c vs. 6g. Within those pairs of compounds, the R 1 substituent is the same, but R 2 substituents differ. This indicates that a possible receptor interaction at the position 4 0 on ring D has less effect on the modulation ability of the indole derivatives as compared to the corresponding PQs. There, 7c vs. 7d and especially 7a vs. 7b show a recognizable difference in modulation. All these findings are consistent with a closer overlap of ring D in the pocket compared to ring A, which is in line with the pharmacophore model (Fig. 2 ).
Conclusions
In this study, we presented a series of 9 indole derivatives 6a-g with a new scaffold based on the pharmacophore of the PQs. The core structure of the compounds was modified by opening the Cring, reducing the size of the B-ring and inserting a carboxylic acid moiety. These modifications resulted in a different polarity profile and, hence, better solubility of the compounds. Additionally, different substituents on the rings defined the diverse characteristic of the compounds. The new compounds modulate the recombinant GABA A receptor combination a1b3, in X. laevis oocytes, whereby a similar SAR also suggests that they share the same binding site with the PQ compounds. We could show that compounds containing a carboxylic acid on ring B and a chlorine atom on ring A exert the highest modulation, whereas indole esters remained inactive. Additionally, the incorporation of a bromine atom on ring D enhanced the efficacy remarkably (Fig. 6 ). The biological data suggest that the more flexible geometry of the indole derivatives leads to a slightly different spatial exploitation of the binding site. Future modifications of the scaffold will be directed towards proving this hypothesis, and are currently ongoing in our laboratories.
Experimental
Materials and instrumentation
Organic solvents were purified when necessary by standard methods or purchased from commercial suppliers [21] . Chemicals were purchased from commercial suppliers and used without further purification. TLC was performed using silica gel 60 aluminium plates containing fluorescent indicator from Merck and detected either with UV light at 254 nm or by charring potassium permanganate (1 g KMnO 4 , 6.6 g K 2 CO 3 , 100 mg NaOH, 100 mL H 2 O in 1 M NaOH) with heating. Flash column chromatography (FC) was carried out at Büchi Sepacore™ MPLC system using silica gel 60 M (particle size 40e63 mm, 230e400 mesh ASTM, Macherey Nagel, Düren). Unless otherwise noted all compounds were purified with a ratio of 1/80 (weight (compound)/weight (silica)). All compounds were obtained in a purity greater than 95% according to NMR. NMR spectra were recorded on a Bruker AC 200 ( 
Synthesis procedures
Synthesis of ethyl-(Z)-2-(2-phenyl)hydrazinylidene)propanoate 2a
Ethyl pyruvate (1.6 equiv.) and acetic acid (0.2 equiv.) were added to a solution of the hydrazine (1 equiv., 5 g, 0.046 mol) in EtOH (50 mL). The reaction was heated to reflux for 2 h. Upon cooling to room temperature, the product crystalized from the reaction mixture. The crystals were collected by filtration and washed with cold EtOH. 2a: 9 g, 97%, colourless solid; 1 Synthesis of ethyl-(Z)-2-(2-(4-Chlorophenyl)hydrazinylidene)propanoate 2b Ethyl pyruvate (1.6 equiv.) and acetic acid (0.2 equiv.) were added to a solution of the hydrazine (1 equiv., 4 g, 0.022 mol) in EtOH (30 mL). The reaction was heated to reflux for 2 h. Upon cooling to room temperature, the product crystalized from the reaction mixture. The crystals were collected by filtration Synthesis of ethyl 1H-indole-2-carboxylate and ethyl 5chloro-1H-indole-2-carboxylate 3b: 2b (1 equiv., 6.51 g, 0.027 mol) and polyphosphoric acid (1:10 w/w) were heated at 100 C for 5 h. The reaction mixture was poured onto ice and the product was extracted with ethyl acetate (3 Â 150 mL). The product was purified by silica gel flash column chromatography (crude material:SiO 2 ¼ 1:100; ethyl acetate: hexane 1:6 to 1:4) to afford 3b (5.8 g, 60%) as a colourless solid. 1 Synthesis of ethyl 5-methoxy-1H-indole-2-carboxylate 3c: 4-Methoxyphenyl-hydrazine (1 equiv., 3 g, 0.017 mol) and ethyl pyruvate (1.1 equiv.) were added consequently to a cooled (0 C) solution of sulfuric acid (3.7 mL) and ethanol (21 mL). The reaction mixture was stirred for 2 h at room temperature. The temperature was increased to 45 C and the reaction was stirred overnight. Upon cooling to room temperature, a precipitate formed. The crude mixture was washed with ethyl acetate to afford 3c as a colourless solid (1.75 g, 46%). 1 Then an ice-cold solution of NaNO 2 (0.18 w/v) in water was added dropwise and the reaction was stirred for 10min. The diazonium salt was kept at 0 C and used immediately after its preparation. Compound 3a, 3b or 3c (1 equiv.) and potassium carbonate (10 equiv.) were suspended in DMF (0.2 M) and cooled to 0 C. Then a solution of the freshly prepared diazonium salt (1.2 equiv.) was added dropwise. Upon the adding a colourful precipitation formed, the reaction was stirred at 0 C for 30 min. The reaction was diluted with water and extracted with ethyl acetate. The product was purified by silica gel flash chromatography (crude material:SiO 2 ¼ 1:100; ethyl acetate: hexane 1:4).
Ethyl
The reaction was carried out according to the general procedure for the synthesis of the ester derivatives with 200 mg of 3a (1 equiv., 1.06 mmol) and delivered 5a as an orange solid (280 mg, 82%). 1 Ethyl (E)-5-chloro-3-((4-methoxyphenyl)diazenyl)-1Hindole-2-carboxylate 5b The reaction was carried out according to the general procedure for the synthesis of the ester derivatives with 80 mg of 3b (1 equiv., 0.36 mmol) and delivered 5b as an orange solid (85 mg, 66%). 1 Ethyl (E)-5-methoxy-3-((4-methoxyphenyl)diazenyl)-1Hindole-2-carboxylate 5c The reaction was carried out according to the general procedure for the synthesis of the ester derivatives with 100 mg of 3c (1 equiv., 0.46 mmol) and delivered 5c as an orange solid (130 mg, 75%). 1 Ethyl (E)-3-((4-bromophenyl)diazenyl)-5-chloro-1H-indole-2-carboxylate 5d The reaction was carried out according to the general procedure for the synthesis of the ester derivatives with 50 mg of 3b (1 equiv., 0.22 mmol) and delivered 5d as an orange solid (60 mg, 70%). 1 Ethyl (E)-5-chloro-3-(p-tolyldiazenyl)-1H-indole-2carboxylate 5f: The reaction was carried out according to the general procedure for the synthesis of the ester derivatives with 50 mg of 3b (1 equiv., 0.22 mmol) and delivered 5f as an orange solid (55 mg, 80%). 1 Ethyl (E)-5-methoxy-3-(p-tolyldiazenyl)-1H-indole-2carboxylate 5g The reaction was carried out according to the general procedure for the synthesis of the ester derivatives with 50 mg of 3c (1 equiv., 0.23 mmol) and delivered 5g as an orange solid (50 mg, 65%). 1 
X-ray single crystal diffraction
Crystals of 6b (CCDC 1844629) were grown by recrystallization from toluene. X-ray diffraction data were collected in a dry stream of nitrogen on a Bruker Kappa APEX II diffractometer system using graphite-monochromatized Mo-Ka radiation (l ¼ 0.71 073 Å) and fine sliced 4and u-scans. Owing to a reconstructive phase transition below ca. 180 K, the crystal was cooled to T ¼ 200 K. Data were reduced to intensity values with SAINT and an absorption correction was applied with the multi-scan approach implemented in SADABS [22] . The structures were solved by the dual-space approach implemented in SHELXT [23] and refined with JANA2006 [24] . Non-hydrogen atoms were refined anisotropically. The H atoms connected to C atoms were placed in calculated positions and thereafter refined as riding on the parent atoms. The carboxylic acid hydrogen atom was located from difference Fourier maps and refined freely. Contributions of disordered solvents to the intensity data were removed using the SQUEEZE routine of the PLATON software suite [25] . Molecular graphics were generated with the program MERCURY [26] .
Two-electrode voltage clamp electrophysiology
All steps were performed as reported previously [6] . In brief, cDNA expression vectors encoding for rat GABA A receptor subunits a1 and b3 were linearized, transcribed and purified in order to generate mRNA. For the microinjection, the RNA of the a1 and b3 receptor combination was mixed at 1:1 ratio with a final concentration of 56 ng/ml. Mature female Xenopus laevis (Nasco, WI) were anaesthetized in a bath of ice-cold 0.17% Tricain (Ethyl-m-aminobenzoate, Sigma, MO) before decapitation and transfer of the frog's ovary to ND96 medium (96 mM NaCl, 2 mM KCl, 1 mM MgCl 2 , 5 mM HEPES; pH 7.5). Stage 5e6 oocytes with the follicle cell layer around them were roughly dissected with forceps into packages of 10e15 cells and washed in Ca 2þ -free ND96 medium. Cells were then digested with collagenase (type IA, Sigma, NO, 1 mg/ml ND96) at 18 C shaking at 70 rpm for 20e40 min and gently defolliculated with a pipette. Defolliculated cells were stored at 18 C for at least 1 h in ND96 solution containing penicillin G (10 000 IU/100 mL) and streptomycin (10 mg/100 mL) in order to preselect and exclude damaged cells from further treatment. Healthy defolliculated oocytes were injected with an aqueous solution of mRNA (2.8ng/ oocyte). The injected oocytes were incubated at 18 C (NDE þ penstrep) for 2e3 days for the a1b3 receptors before recording. For electrophysiological recordings, oocytes were impaled with two microelectrodes (1e3 MU) filled with 2 M KCl and constantly washed by a flow of 6 mL/min NDE medium [96 mM NaCl, 5 mM HEPES-NaOH (pH 7.5), 2 mM KCl, 1 mM MgCl 2 x 6H 2 O, 1.8 mM CaCl 2 x2H 2 O] that could be switched to NDE containing GABA and/or test compounds. Compounds were diluted into NDE from DMSO-solutions resulting in a final concentration of 0.1% DMSO perfusing the oocytes and co-applied with GABA until a peak response was observed. To test for modulation of GABA induced currents, a concentration of GABA, which was titrated to trigger 3e5% in ab receptors of the respective maximum GABA-elicited current, was applied to the cell with increasing concentrations of compounds. All recordings were performed at room temperature at a holding potential of À60 mV using a Dagan TEV-200A two-electrode voltage clamp (Dagan Corporation, Mineapolis, MN). Data were digitized, recorded and measured using an Axon Digidata 1550 low-noise data acquisition system (Axon Instruments, Union City, CA). Data acquisition was done using pCLAMP v.10.5 (Molecular Devices™, Sunnyvale, CA). Data were analysed using GraphPad Prism v.6. and plotted as bar diagrams/bar graphs. Data are given as mean ± SEM from at least three oocytes of two and more oocyte batches.
